secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2026-05-14T12:10:16+00:00
Accession:  0001493152-26-022881
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate Q1 net loss widens to $9.3M; cash at $25.9M; CTx-1301 PDUFA May 31
----------------------------------------------------------------------------

- Net loss of $9.3M for Q1 2026, up from $3.9M a year ago; G&A expenses surged to $5.7M on commercial build-out.
- Cash and cash equivalents $25.9M at Mar 31, up $14.9M from Dec 31, extending runway into 2027.
- FDA review of CTx-1301 NDA ongoing; PDUFA target action date remains May 31, 2026.
- Commercial readiness advanced with AI-driven tools and IQVIA sales force agreement for potential launch.
- R&D expenses decreased 1.8% to $2.2M as clinical studies concluded, partly offset by regulatory and CMC activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315226022881/0001493152-26-022881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315226022881/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer